A summary of the National Cancer Institute Think Tank on Advancing Gastric Cancer Prevention
Authors:
- M Constanza CamargoMCM Constanza Camargo
- Christian C AbnetCAChristian C Abnet
- Jeremy L DavisJDJeremy L Davis
- Cecilia MongeCMCecilia Monge
- Tram Kim LamTLTram Kim Lam
- Matthew YoungMYMatthew Young
- Phil DaschnerPDPhil Daschner
- Tiffany A WallaceTWTiffany A Wallace
- Philip E CastlePCPhilip E Castle
- Asad UmarAUAsad Umar
- 2 July 2025
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2169-2174
Abstract
Gastric cancer remains a major health challenge globally. In the United States, gastric cancer outcomes remain poor, with well-documented disparities in incidence and mortality. In 2024, the US National Cancer Institute convened a Think Tank on Advancing Gastric Cancer Prevention, with participation of over 200 global leaders from academia, clinical practice, and industry as well as patient advocates to exchange knowledge, lived experiences, and discuss future research opportunities. This commentary summarizes the Think Tank presentations and discussions of key existing evidence as well as challenges and opportunities for the prevention and control of this preventable disease. Primary prevention discussions focused on the use of the screen-and-treat strategy for Helicobacter pylori eradication. Secondary prevention discussions included endoscopic screening and surveillance of advanced gastric precancerous lesions. Primary conclusions for gastric cancer prevention and control included the need for (1) developing large-scale study resources that optimize the ability to conduct research with potential clinical translation applications; (2) strengthening and building community-public health-academic partnerships to enhance research; and (3) leveraging evidence-based strategies developed in high-risk East Asian countries to high-risk subgroups in low- and moderate-risk countries including the United States. There was overwhelming agreement that given the current state of gastric cancer incidence and survival in the United States, novel strategies to control the carcinogenic effects of H. pylori and to improve detection of precursors are the key to substantially reducing the burden of this disease.Keywords
Funding Information
- National Cancer Institute
- National Institutes of Health
- Departement of Heath and Human Services
This publication has 28 references indexed in Scilit:
- Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese PopulationCancer Medicine, 2025
- Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease‐Specific MortalityUnited European Gastroenterology Journal, 2025
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Screening for Helicobacter pylori to Prevent Gastric CancerJAMA, 2024
- Fecal Immunochemical Test and Helicobacter pylori Stool Antigen Co-TestingJAMA, 2024
- Quality indicators for upper GI endoscopyGastrointestinal Endoscopy, 2024
- Incidence and Survival Outcomes of Gastrointestinal Stromal TumorsJAMA Network Open, 2024
- Epidemiology of Gastric Malignancies 2000–2018 According to Histology: A Population-Based Analysis of Incidence and Temporal TrendsClinical Gastroenterology and Hepatology, 2023
- Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric CancerJAMA Oncology, 2021
- Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer preventionBest Practice & Research Clinical Gastroenterology, 2013